Back HCV Treatment

EASL 2015: Gilead Triple Combination Cures Easy-To-Treat Hepatitis C Patients in 6 Weeks

A 6-week regimen of sofosbuvir (Sovaldi) plus 2 experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis C virus and no liver cirrhosis, according to a poster presentation at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. A 4-week regimen was not effective for any group, however, and 6 weeks appears inadequate for harder-to-treat patients. Other studies showed that the new drugs -- GS-5816 (velpatasvir) and GS-9857 -- are also active against other HCV genotypes.


Read more: